SCHEMBL7940967

SCHEMBL7940967

Nc1ncccc1NCc1cccc(NC(=O)c2cc3cc(Cl)ccc3o2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 0.57
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
GRM4 Q14833 1/20 0.45
AURKA O14965 5/20 0.45
AURKB Q96GD4 4/20 0.45
RPS6KB1 P23443 1/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
TP53 P04637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7940374 0.89 RAB9A (0.58) BACE1NPC1RAB9AAURKAAURKB
SCHEMBL7941663 0.89 BACE1 (0.58) BACE1NPC1RAB9AKMT2AMEN1
SCHEMBL7946768 0.88 NPC1 (0.47) BACE1NPC1RAB9AGRM4KMT2A
SCHEMBL7939890 0.86 NPC1 (0.46) BACE1NPC1RAB9AKMT2AMEN1
SCHEMBL7932672 0.86 BACE1 (0.62) BACE1NPC1RAB9AAURKAAURKB
SCHEMBL7939891 0.84 BACE1 (0.56) BACE1NPC1RAB9AAURKAAURKB
SCHEMBL7944671 0.83 BACE1 (0.64) BACE1NPC1RAB9AGRM4AURKA
SCHEMBL7942885 0.83 BACE1 (0.61) BACE1NPC1RAB9AGRM4AURKA
SCHEMBL7944661 0.82 BACE1 (0.71) BACE1GRM4AURKAAURKBRPS6KB1
SCHEMBL7942206 0.81 BACE1 (0.66) BACE1GRM4AURKAAURKBRPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885NPC1 431/4885RAB9A 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.